skip to Main Content


Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."


United Healthcare Home Immunotherapy Policy Change

United Healthcare has recently announced a policy change. Effective January 1, 2023, UHC will no longer…

Read more

Medicare 2022 Conversion Factor Update

Thanks to lobbying efforts from the House of Medicine, Congress took action this month. The…

Read more

CY 2022 Physician Fee Schedule Proposed Rule Summary

On July 13, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

Read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

06/01/23: Research Grant Cycle
Learn more

06/26/23: Membership Application Deadline to be eligible for AAOA Member rate for the 2023 Basic Course

07/01/23: Scientific Abstract Submission Deadline
Learn more

12/01/23: Research Grant Cycle
Learn more

04/01/24: Fellow Exam Application Deadline
Learn more


2023 AAOA Annual Meeting

Register Now to access over 19 hrs of CME | Continuing Certification through our 2023 Hybrid Annual Meeting. The meeting will take place in Nashville and virtually from September 29 - October 1, 2023. On-Demand post course access will be open until November 14, 2023. Learn More


For information about Resident opportunities, DosedDaily, research grants, and other resources. Learn More


Available Now


IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2023 AAOA Basic Course in Allergy & Immunology - Hybrid
September 1 - Access
Learn More and Register

2023 AAOA Annual Meeting - Hybrid
September 29 – October 1, 2023
Embassy Suites by Hilton Nashville Downtown
Learn More and Register

2024 AAOA Advanced Course in Allergy & Immunology - Hybrid
February 8 - 10, 2024
Hyatt Regency Tamaya
Santa Ana Pueblo, New Mexico
(outside Albuquerque)

2024 AAOA Basic Course in Allergy & Immunology - Hybrid
July 25-27, 2024
The Diplomat, Hollywood, Florida
Learn More and Get Hotel Room

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Next Availability - November 1, 2023

News and Updates

National Study to Document Changes in Physician Practice Expense

The American Medical Association (AMA) is undertaking a new national study, supported by 173 healthcare organizations,…

Read more

American Elm Shortage

American Elm is dying from Dutch Elm Disease. This may explain the concentrate shortage many practices…

Read more
College Allergy Symptoms Treatment Back to Shcool


AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More


AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>


Hypoallergenic Pet Food: Myth or Magic Solution?

By Alfred Sassler, DO, AAOA PPR Commitee

A major pet food producer is marketing a “groundbreaking” cat food to reduce cat allergens. It was released after 10 years of development and testing to produce a nutritional solution to reduce house cat allergy production. It even comes in a variety of tantalizing, and nutritionally sound, flavor choices according to the manufacturer.

Is this too good to be true?

The main cat antigen

Fel d 1 is the small glycoprotein antigen that is most important for cat allergic people. The antigen is small enough to float in the air and also quite sticky.  It is concentrated in saliva and sebaceous gland secretions allowing cats to spread it to the haircoat when grooming. It is subsequently distributed into the air and can stick to fabrics or other surfaces. When cat allergic people contact Fel d 1, allergy symptoms and asthma exacerbations can occur.

Blocking antibodies

Antibodies that block the immunologic activity of specific antigens are called blocking antibodies. Chicken eggs can be induced to produce IgY blocking antibody for Fel d 1 that is active in cat saliva. These IgY antigens have already been used in animal feed for other conditions. Why not try this for cat antigen?

IgY against Fel d 1 was added to cat food to block the activity of Fel d 1 in the cat’s saliva.

Impact of adding Fel d 1 IgY antibodies to cat food

The company reports a median reduction on 47% of active antigen in 6 weeks. In cats that produced higher levels of Fel d 1, the reduction was even higher. There were no adverse health impacts for the cats.

Is this reduction enough to help with symptoms?

We who treat allergy will usually explain to patient’s that if they can cut down the exposure to their specific allergens, they will have less reactivity (fewer symptoms). However, there is an old adage that a patient is more likely to get rid of their Allergist than their beloved pet!  

Additionally, animal removal is not completely effective as Fel d 1 has been detected up to 9 months after removal.  For example, in a rigorous 2003 study by a group from Iceland, (Bjornsdottir and colleagues) a group of volunteer families strictly followed very stringent environmental control measures while keeping their pets in the home.  These included washing walls and floors, removing carpeting from bedrooms, keeping closets closed, vacuuming floors, carpets and upholstered furniture weekly, applying tannic acid (3%) to carpeting and furniture every 2 months, hot water washing of bedding, replacing old duvets and pillows with polyester filled new ones, hypoallergenic covers on pillows and mattresses, washing the cat every 2 weeks, keeping cat out of bedroom and sleeping with bedroom windows open.  After 8 months, the amount of Fel d1 in the houses decreased by 6.8%. 

While this may not seem like a lot, it did result in significant symptom improvement for the cat allergy sufferers.  The mean nasal peak inspiratory flow increased from 154.9ml to 216.7ml at the 8-month conclusion of the study.  There were also measurable improvements in symptoms of congestion, runny nose and itching. 


This new cat food may actually cut down on allergen exposure and symptoms. However, much of the existing available data is from the company itself with limited prospective data on the clinical impact of this cat food on the symptoms of cat allergic patients.

Given the marketing and branding of this cat food, patients are likely to ask about it so we should be familiar with the available data. It is a low-risk option to try for cat allergic patients seeking additional methods to reducing their symptoms. This food is about 5 times more expensive than other options available from the same company (~ $5 per pound of dry food versus $1 per pound).

The Claim“Groundbreaking” new cat food that is safe and effective at reducing production of cat allergens.
The ScienceIgY chicken egg-derived blocking antigens have been used in other animal feeds for other conditions. Fel d 1 IgY blocking antigens have been shown to reduce production and activity of Fel d 1. The company reported a mean 47% decrease in active Fel d 1 in saliva at 6 weeks
Other OptionsStrict environmental controls à 6.8% decrease in Fel d 1Controls included: washing walls and floors, removing carpeting from bedrooms, weekly vacuuming of carpets and upholstered surfaces, applying tannic acid (3%) to carpeting and furniture every 2 months, hot water washing of bedding, replacing old duvets and pillows with polyester filled new ones, hypoallergenic covers on pillows and mattresses, washing the cat every two weeks, keeping cat out of bedroom, and sleeping with bedroom windows openStrict environmental control improved:Mean nasal peak inspiratory flow increased from 154.9ml to 216.7mlSymptoms of congestion, runny nose, and itching. 
The VerdictNo definitive evidence of clinical efficacy in our patientsUnlikely to harm our patients (or their pets) and may helpThe special cat food is significantly more expensive than other options from the same company


Satyaraj, E., Gardner, C., Filipi, I., Cramer, K. & Sherrill, S. (2019). Reduction of active Fel d 1 from cats using an antiFel d 1 egg IgY antibody. Immunity, Inflammation & Disease. Advance online publication. doi: 10.1002/iid3.244

Matulka RA, Thompson L, Corley D. Multi-Level Safety Studies of Anti Fel d 1 IgY Ingredient in Cat Food. Front Vet Sci. 2020 Jan 8;6:477. doi: 10.3389/fvets.2019.00477. PMID: 31970163; PMCID: PMC6960183.

Satyaraj E, Gardner C, Filipi I, Cramer K, Sherrill S. Reduction of active Fel d1 from cats using an antiFel d1 egg IgY antibody. Immun Inflamm Dis. 2019 Jun;7(2):68-73. doi: 10.1002/iid3.244. Epub 2019 Mar 9. PMID: 30851084; PMCID: PMC6485700.

Back To Top